USE OF ADENOSINE A1 ANTAGONISTS IN RADIOCONTRAST MEDIA INDUCED NEPHROPATHY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 31, 2008
app pub date -
Jun 19, 2007
filing date -
Jun 19, 2006
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Described herein are pharmaceutical combinations comprising a therapeutically effective amount of a first selective adenosine A1 antagonist and a first radiocontrast media. In one embodiment the selective adenosine A1 antagonist comprises 4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-trans-cyclohexanol methanesulfonate and/or (4S)-4-hydroxy-1-(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-L-prolinamide methanesulfonate. Also described are the use of a first selective adenosine A1 antagonist in the treatment of radiocontrast media induced nephropathy. Furthermore, a kit comprising a therapeutically effective amount of a first selective adenosine A1 antagonist and a first radiocontrast media is also described herein.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully